- Home
- MFIN vs AMRN Comparison
MFIN vs AMRN Comparison
Compare MFIN & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MFIN | AMRN |
|---|---|---|
| Founded | 1995 | 1989 |
| Country | United States | Ireland |
| Employees | 179 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.7M | 287.9M |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | MFIN | AMRN |
|---|---|---|
| Price | $11.98 | $13.63 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 1 | 1 |
| Target Price | $12.00 | $12.00 |
| AVG Volume (30 Days) | 55.1K | ★ 76.1K |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | ★ 5.18% | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.02 | $1.26 |
| P/E Ratio | $6.21 | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $7.85 | $12.96 |
| 52 Week High | $12.26 | $20.90 |
Technical Indicators
Market Signals| Indicator | MFIN | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 58.10 | 42.10 |
| Support Level | $9.50 | $13.48 |
| Resistance Level | $12.26 | $14.50 |
| Average True Range (ATR) | 0.27 | 0.40 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 61.85 | 37.76 |
Price Performance
Historical ComparisonAbout MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The four operating segments are, (1) recreation, (2) home improvement, (3) commercial and (4) taxi medallion The company generates maximum revenue from the Recreation segment. The company's geographic Concentrations are in united states diversified in California, Wisconsin, New York, Texas and others.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.